News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeClinical Forum InsightsMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
ACTRIMS 2026|
ISC 2026
Advertisement

Julia A. Wall

Advertisement

Articles by Julia A. Wall

A Team Approach to Asleep Deep Brain Stimulation

ByJason M. Schwalb, MD,Ellen L. Air, MD, PhD,Neepa J. Patel, MD,Julia A. Wall
December 25th 2020

Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

    1

    Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis

    2

    Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers

    3

    Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD

    4

    Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib

    5

    CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis

    • About Us
    • Advisory Board
    • Editorial
    • Contact Us
    • Advertise
    • Contact MJH LS
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Contagion Live
    • CGT Live
    • Neurology Live
    • HCP Live
    • Oncology Live
    • Contemporary Pediatrics
    • Contemporary OBGYN
    • Urology Times
    • The Educated Patient
    HCP Live
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us